RxDoctor Payments Data

Ganesh Ghooray, MD

Neurology · Indianapolis, INNPI 1144227042

Payments from drug & device makers

$18,126in general payments, 2019–2025

Across 1,160 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Novartis$1K
  • Neurocrine Biosciences, Inc.$899
  • Teva Pharmaceuticals USA, Inc.$835
  • Lilly USA, LLC$827
  • plus $10K from 53 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$17,88899%
  • Education$2171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)169$2,277
UCB, Inc.107$1,836
Novartis77$1,103
Neurocrine Biosciences, Inc.58$899
Teva Pharmaceuticals USA, Inc.49$835
Lilly USA, LLC54$827
AstraZeneca(2 entities)43$780
MDD US Operations, LLC42$699
Amgen(2 entities)36$696
Amneal Pharmaceuticals LLC43$628
Sunovion Pharmaceuticals Inc.63$598
Lundbeck LLC34$566
Sanofi29$557
Biogen34$556
SK Life Science, Inc.34$501
Eisai Inc.22$446
Supernus Pharmaceuticals, Inc.31$417
Livanova USA, Inc.21$398
Argenx US, Inc.26$327
EMD Serono, Inc.31$303
Pfizer15$273
Banner Life Sciences, LLC11$226
CSL Behring12$206
Avanir Pharmaceuticals, Inc.11$195
Acadia Pharmaceuticals Inc10$184
Genentech USA, Inc.12$170
Jazz Pharmaceuticals Inc.7$167
Sumitomo Pharma America, Inc.9$112
Adamas Pharmaceuticals, Inc.6$110
Impel Pharmaceuticals Inc.5$97
Vanda Pharmaceuticals Inc.3$80
Catalyst Pharmaceuticals, Inc.3$74
Upsher-smith Laboratories LLC4$72
Johnson & Johnson4$70
Cycle Pharmaceuticals Inc3$65
Aprecia Pharmaceuticals, LLC3$61
Biohaven Pharmaceuticals, Inc.3$56
Harmony Biosciences LLC2$56
Springworks Therapeutics, Inc.2$50
Otsuka America Pharmaceutical, Inc.2$49
Acorda Therapeutics, Inc3$47
Zyla Life Sciences, Inc.2$42
Alnylam Pharmaceuticals Inc.3$41
Promius Pharma LLC2$38
Grifols USA, LLC2$35
Biohaven Pharmaceutical Holding Company Ltd.2$34
Merz Pharmaceuticals, LLC1$30
Arbor Pharmaceuticals, Inc.2$30
Kyowa Kirin, Inc.2$27
Scilex Pharmaceuticals Inc.1$25
Aquestive Therapeutics, Inc.2$25
Neurelis, Inc.1$20
GE HealthCare1$19
Corium, LLC1$18
TG Therapeutics, Inc.1$16
Takeda Pharmaceuticals U.S.A., Inc.1$15
Tanabe Pharma America, Inc.1$15
Medtronic1$14
Axsome Therapeutics, Inc.1$13

How this compares

$18,126 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$147,062
Medicare patients
453
Services billed
7,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab13$110,749
NuplazidPimavanserin Tartrate15$107,625
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5016$74,744
CopaxoneGlatiramer Acetate11$64,152
Nurtec OdtRimegepant Sulfate24$34,707
AptiomEslicarbazepine Acetate13$24,612
NeuproRotigotine12$19,414
Emgality PenGalcanezumab-Gnlm19$14,499
Entacapone13$4,430
Carbamazepine ErCarbamazepine32$3,584
DilantinPhenytoin Sodium Extended21$3,482
Levetiracetam112$3,080
Lacosamide31$3,051
AmantadineAmantadine Hcl39$2,734
Memantine Hcl131$2,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$184$107,62515 claims
CSL BehringPrivigen$206$74,74416 claims
Teva Pharmaceuticals USA, Inc.Copaxone$835$64,15211 claims
PfizerNurtec Odt, Dilantin, Dilantin$273$38,80658 claims
Sunovion Pharmaceuticals Inc.Aptiom$598$24,61213 claims
UCB, Inc.Neupro$1,836$19,41412 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$628$88318 claims
Upsher-smith Laboratories LLCTopiramate$72$37466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →